Study Details

Back to Search Results

A Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

This trial is recruiting

Clinicaltrials.gov ID

NCT04240002

Astellas Study ID

2215-CL-0603

EudraCT ID

2018-002301-61

Follow Trial

Condition

Leukemia - AML

Phase

Phase 1

Age

6 Months - 21 Years

Sex

Female & Male

Product

gilteritinib

Type

Interventional

Trial Dates

Sep 2020 - Sep 2026

Masking

None (Open Label)

Enrollment number

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)? Contact us by filling our your information to the right and we’ll respond to you.

Requestor Information [I am…]

First name*

Last name*

Email*

Country/Region*

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

I give my consent to the processing of my personal data mentioned above according to Astellas Privacy Notice & Cookies Policy

Locations

Site CA15001

Montreal, Canada, H3T 1C5

Recruiting

Site GB44001

Birmingham, United Kingdom, B4 6NH

Recruiting

SIte IT39001

Roma, Italy, 165

Recruiting

Site DE49004

Essen, Germany, 45147

Recruiting

Site DE49003

Regensburg, Germany, 93053

Recruiting

Site GB44003

Glasgow, United Kingdom, G51 4TF

Recruiting

Site IT39002

Monza, Italy, 20900

Recruiting

Site IT39003

Bologna, Italy, 40138

Recruiting

Site DE49001

Halle (Saale), Germany, 06120

Recruiting

Site ES34003

Sevilla, Spain, 41013

Recruiting

Site DE49002

Freiburg, Germany, 79106

Recruiting

Site GB44005

Cardiff, United Kingdom, CF14 4XW

Recruiting

Site GB44006

Bristol, United Kingdom, BS2 8BJ

Recruiting

Site ES34001

Barcelona, Spain, 08950

Recruiting

Site ES34002

Barcelona, Spain, 08950

Recruiting

Sarah Cannon Research Institute

Nashville, United States, 37203

Recruiting

Cincinnati Children's Hospital Medical Center

Cincinnati, United States, 45229

Recruiting

The Children's Hospital of Philadelphia (CHOP)

Philadelphia, United States, 19104

Recruiting

St. Jude Children's Research Hospital

Memphis, United States, 38105

Recruiting

Site UK44007

Sutton, United Kingdom

Recruiting

Site FR33005

Paris, France

Recruiting

Site FR33006

Paris, France

Recruiting

Site FR33004

Marseille cedex 05, France

Recruiting

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website